Cargando…
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
BACKGROUND: The four intrinsic subtypes of breast cancer, defined by differential expression of 50 genes (PAM50), have been shown to be predictive of risk of recurrence and benefit of hormonal therapy and chemotherapy. Here we describe the development of Prosigna™, a PAM50-based subtype classifier a...
Autores principales: | Wallden, Brett, Storhoff, James, Nielsen, Torsten, Dowidar, Naeem, Schaper, Carl, Ferree, Sean, Liu, Shuzhen, Leung, Samuel, Geiss, Gary, Snider, Jacqueline, Vickery, Tammi, Davies, Sherri R., Mardis, Elaine R., Gnant, Michael, Sestak, Ivana, Ellis, Matthew J., Perou, Charles M., Bernard, Philip S., Parker, Joel S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546262/ https://www.ncbi.nlm.nih.gov/pubmed/26297356 http://dx.doi.org/10.1186/s12920-015-0129-6 |
Ejemplares similares
-
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
por: Nielsen, Torsten, et al.
Publicado: (2014) -
Research-based PAM50 signature and long-term breast cancer survival
por: Pu, Minya, et al.
Publicado: (2019) -
Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
por: Kjällquist, Una, et al.
Publicado: (2022) -
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
por: Jensen, Maj-Britt, et al.
Publicado: (2020) -
Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)